ASX - By Stock
|
EM2 |
Re:
Ann: Mineral Resource Estimate Increased to 28Mt @ 1.35% Copper
|
|
SAtoe3
|
77 |
30K |
1 |
06/06/24 |
06/06/24 |
ASX - By Stock
|
77
|
30K
|
1
|
|
ASX - By Stock
|
EM2 |
Re:
Ann: Change in Director Interests
|
|
SAtoe3
|
3 |
1.1K |
2 |
30/03/24 |
30/03/24 |
ASX - By Stock
|
3
|
1.1K
|
2
|
|
ASX - By Stock
|
EM2 |
Re:
Ann: Change in Director Interests
|
|
SAtoe3
|
3 |
1.1K |
0 |
29/03/24 |
29/03/24 |
ASX - By Stock
|
3
|
1.1K
|
0
|
|
ASX - By Stock
|
EM2 |
Re:
Q&A with Tim Mason of Eagle Mountain Mining
|
|
SAtoe3
|
2 |
994 |
3 |
24/02/24 |
24/02/24 |
ASX - By Stock
|
2
|
994
|
3
|
|
ASX - By Stock
|
PER |
Re:
6 months passed since first patient
|
|
SAtoe3
|
161 |
39K |
4 |
10/02/24 |
10/02/24 |
ASX - By Stock
|
161
|
39K
|
4
|
|
ASX - By Stock
|
PER |
Re:
6 months passed since first patient
|
|
SAtoe3
|
161 |
39K |
3 |
08/02/24 |
08/02/24 |
ASX - By Stock
|
161
|
39K
|
3
|
|
ASX - By Stock
|
PER |
Re:
6 months passed since first patient
|
|
SAtoe3
|
161 |
39K |
5 |
07/02/24 |
07/02/24 |
ASX - By Stock
|
161
|
39K
|
5
|
|
ASX - By Stock
|
EM2 |
Re:
Ann: Mineral Resource Estimate Increased to 28Mt @ 1.35% Copper
|
|
SAtoe3
|
77 |
30K |
5 |
30/11/23 |
30/11/23 |
ASX - By Stock
|
77
|
30K
|
5
|
|
ASX - By Stock
|
PER |
Re:
anp chart
|
|
SAtoe3
|
1.0K |
303K |
5 |
30/11/23 |
30/11/23 |
ASX - By Stock
|
1.0K
|
303K
|
5
|
|
ASX - By Stock
|
PER |
Re:
Reject Name Change Resolution
|
|
SAtoe3
|
43 |
13K |
12 |
11/11/23 |
11/11/23 |
ASX - By Stock
|
43
|
13K
|
12
|
|
ASX - By Stock
|
PER |
Re:
For General Information
|
|
SAtoe3
|
3.5K |
1.0M |
9 |
11/10/23 |
11/10/23 |
ASX - By Stock
|
3.5K
|
1.0M
|
9
|
|
ASX - By Stock
|
PER |
Re:
For General Information
|
|
SAtoe3
|
3.5K |
1.0M |
7 |
10/10/23 |
10/10/23 |
ASX - By Stock
|
3.5K
|
1.0M
|
7
|
|
ASX - By Stock
|
PER |
Re:
For General Information
|
|
SAtoe3
|
3.5K |
1.0M |
7 |
09/10/23 |
09/10/23 |
ASX - By Stock
|
3.5K
|
1.0M
|
7
|
|
ASX - By Stock
|
PER |
Re:
Ann: Antisense launches Unmarketable Parcels facility
|
|
SAtoe3
|
9 |
2.8K |
4 |
09/10/23 |
09/10/23 |
ASX - By Stock
|
9
|
2.8K
|
4
|
|
ASX - By Stock
|
PER |
Re:
For General Information
|
|
SAtoe3
|
3.5K |
1.0M |
8 |
05/10/23 |
05/10/23 |
ASX - By Stock
|
3.5K
|
1.0M
|
8
|
|
ASX - By Stock
|
PER |
Re:
Ann: Positive Data for ATL1102 in Limb Girdle Muscular Dystrophy
|
|
SAtoe3
|
65 |
16K |
12 |
27/09/23 |
27/09/23 |
ASX - By Stock
|
65
|
16K
|
12
|
|
ASX - By Stock
|
PER |
Re:
Prof Thomas Voit, DMD expert, interview with Wilsons advisory
|
|
SAtoe3
|
47 |
15K |
3 |
24/09/23 |
24/09/23 |
ASX - By Stock
|
47
|
15K
|
3
|
|
ASX - By Stock
|
PER |
Re:
For General Information
|
|
SAtoe3
|
3.5K |
1.0M |
3 |
20/09/23 |
20/09/23 |
ASX - By Stock
|
3.5K
|
1.0M
|
3
|
|
ASX - By Stock
|
PER |
Re:
For General Information
|
|
SAtoe3
|
3.5K |
1.0M |
5 |
18/09/23 |
18/09/23 |
ASX - By Stock
|
3.5K
|
1.0M
|
5
|
|
ASX - By Stock
|
PER |
Re:
For General Information
|
|
SAtoe3
|
3.5K |
1.0M |
10 |
18/09/23 |
18/09/23 |
ASX - By Stock
|
3.5K
|
1.0M
|
10
|
|
ASX - By Stock
|
PER |
Re:
Ann: Antisense Therapeutics Corporate Presentation
|
|
SAtoe3
|
82 |
23K |
9 |
12/09/23 |
12/09/23 |
ASX - By Stock
|
82
|
23K
|
9
|
|
ASX - By Stock
|
PER |
Re:
For General Information
|
|
SAtoe3
|
3.5K |
1.0M |
7 |
11/09/23 |
11/09/23 |
ASX - By Stock
|
3.5K
|
1.0M
|
7
|
|
ASX - By Stock
|
PER |
Re:
For General Information
|
|
SAtoe3
|
3.5K |
1.0M |
18 |
10/09/23 |
10/09/23 |
ASX - By Stock
|
3.5K
|
1.0M
|
18
|
|
ASX - By Stock
|
PER |
Re:
For General Information
|
|
SAtoe3
|
3.5K |
1.0M |
13 |
05/09/23 |
05/09/23 |
ASX - By Stock
|
3.5K
|
1.0M
|
13
|
|
ASX - By Stock
|
PER |
Re:
For General Information
|
|
SAtoe3
|
3.5K |
1.0M |
35 |
05/09/23 |
05/09/23 |
ASX - By Stock
|
3.5K
|
1.0M
|
35
|
|
ASX - By Stock
|
PER |
Re:
Ann: Antisense Therapeutics Corporate Presentation
|
|
SAtoe3
|
82 |
23K |
8 |
29/08/23 |
29/08/23 |
ASX - By Stock
|
82
|
23K
|
8
|
|
ASX - By Stock
|
PER |
Re:
For General Information
|
|
SAtoe3
|
3.5K |
1.0M |
1 |
24/08/23 |
24/08/23 |
ASX - By Stock
|
3.5K
|
1.0M
|
1
|
|
ASX - By Stock
|
PER |
Re:
For General Information
|
|
SAtoe3
|
3.5K |
1.0M |
4 |
24/08/23 |
24/08/23 |
ASX - By Stock
|
3.5K
|
1.0M
|
4
|
|
ASX - By Stock
|
PER |
Re:
For General Information
|
|
SAtoe3
|
3.5K |
1.0M |
1 |
24/08/23 |
24/08/23 |
ASX - By Stock
|
3.5K
|
1.0M
|
1
|
|
ASX - By Stock
|
PER |
Re:
James Garner AKA JG
|
|
SAtoe3
|
190 |
49K |
3 |
19/08/23 |
19/08/23 |
ASX - By Stock
|
190
|
49K
|
3
|
|
ASX - By Stock
|
PER |
Re:
James Garner AKA JG
|
|
SAtoe3
|
190 |
49K |
7 |
18/08/23 |
18/08/23 |
ASX - By Stock
|
190
|
49K
|
7
|
|
ASX - By Stock
|
PER |
Re:
James Garner AKA JG
|
|
SAtoe3
|
190 |
49K |
6 |
16/08/23 |
16/08/23 |
ASX - By Stock
|
190
|
49K
|
6
|
|
ASX - By Stock
|
PER |
Re:
James Garner AKA JG
|
|
SAtoe3
|
190 |
49K |
10 |
15/08/23 |
15/08/23 |
ASX - By Stock
|
190
|
49K
|
10
|
|
ASX - By Stock
|
PER |
Re:
James Garner AKA JG
|
|
SAtoe3
|
190 |
49K |
16 |
06/08/23 |
06/08/23 |
ASX - By Stock
|
190
|
49K
|
16
|
|
ASX - By Stock
|
PER |
Re:
Other indications
|
|
SAtoe3
|
64 |
16K |
15 |
02/08/23 |
02/08/23 |
ASX - By Stock
|
64
|
16K
|
15
|
|
ASX - By Stock
|
PER |
Re:
Other indications
|
|
SAtoe3
|
64 |
16K |
2 |
01/08/23 |
01/08/23 |
ASX - By Stock
|
64
|
16K
|
2
|
|
ASX - By Stock
|
PER |
Re:
Ann: Institutional Placement and proposed Share Purchase Plan SPP
|
|
SAtoe3
|
71 |
19K |
7 |
21/07/23 |
21/07/23 |
ASX - By Stock
|
71
|
19K
|
7
|
|
ASX - By Stock
|
PER |
Re:
Ann: Quarterly Activities Report
|
|
SAtoe3
|
5 |
1.3K |
0 |
20/07/23 |
20/07/23 |
ASX - By Stock
|
5
|
1.3K
|
0
|
|
ASX - By Stock
|
PER |
Re:
Ann: Quarterly Activities Report
|
|
SAtoe3
|
5 |
1.3K |
2 |
20/07/23 |
20/07/23 |
ASX - By Stock
|
5
|
1.3K
|
2
|
|
ASX - By Stock
|
PER |
Re:
Ann: Trading Halt
|
|
SAtoe3
|
158 |
44K |
1 |
15/07/23 |
15/07/23 |
ASX - By Stock
|
158
|
44K
|
1
|
|
ASX - By Stock
|
PER |
Re:
Ann: Shareholder Newsletter
|
|
SAtoe3
|
98 |
29K |
11 |
07/07/23 |
07/07/23 |
ASX - By Stock
|
98
|
29K
|
11
|
|
ASX - By Stock
|
PER |
Re:
Ann: MHRA approval for ATL1102 Phase IIb DMD clinical trial in UK
|
|
SAtoe3
|
29 |
8.3K |
8 |
27/06/23 |
27/06/23 |
ASX - By Stock
|
29
|
8.3K
|
8
|
|
ASX - By Stock
|
PER |
Re:
Ann: MHRA approval for ATL1102 Phase IIb DMD clinical trial in UK
|
|
SAtoe3
|
29 |
8.3K |
11 |
27/06/23 |
27/06/23 |
ASX - By Stock
|
29
|
8.3K
|
11
|
|
ASX - By Stock
|
PER |
Re:
For General Information
|
|
SAtoe3
|
3.5K |
1.0M |
6 |
26/06/23 |
26/06/23 |
ASX - By Stock
|
3.5K
|
1.0M
|
6
|
|
ASX - By Stock
|
PER |
Re:
For General Information
|
|
SAtoe3
|
3.5K |
1.0M |
4 |
22/06/23 |
22/06/23 |
ASX - By Stock
|
3.5K
|
1.0M
|
4
|
|
ASX - By Stock
|
PER |
Re:
For General Information
|
|
SAtoe3
|
3.5K |
1.0M |
7 |
15/06/23 |
15/06/23 |
ASX - By Stock
|
3.5K
|
1.0M
|
7
|
|
ASX - By Stock
|
PER |
Re:
Ann: Positive outcomes in DMD combination therapy animal study
|
|
SAtoe3
|
124 |
36K |
7 |
12/06/23 |
12/06/23 |
ASX - By Stock
|
124
|
36K
|
7
|
|
ASX - By Stock
|
PER |
Re:
anp chart
|
|
SAtoe3
|
1.0K |
303K |
7 |
10/06/23 |
10/06/23 |
ASX - By Stock
|
1.0K
|
303K
|
7
|
|
ASX - By Stock
|
PER |
Re:
anp chart
|
|
SAtoe3
|
1.0K |
303K |
23 |
09/06/23 |
09/06/23 |
ASX - By Stock
|
1.0K
|
303K
|
23
|
|
ASX - By Stock
|
PER |
Re:
Ann: First Patient Dosed in ATL1102 Phase IIb DMD Trial
|
|
SAtoe3
|
34 |
12K |
1 |
09/06/23 |
09/06/23 |
ASX - By Stock
|
34
|
12K
|
1
|
|